BIO-TECHNE Corp(TECH)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #966 of 2,961 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
TECH Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for BIO-TECHNE Corp (TECH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TECH at 58.9/100 on a 32-signal composite quality model, placing it at rank #966 of 2,961 stocks — the top half of the AI-ranked universe. TECH scores in the top quartile across profitability (79.0), earnings quality (77.8), balance sheet strength (77.1). Areas of concern include revenue growth (32.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIO-TECHNE Corp reports quarterly revenue of $321.2M, net income of $54.6M, free cash flow of $86.9M. Top institutional holders of TECH by reported 13-F value include BlackRock, FMR, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. TECH trades on the Nasdaq exchange and files with the SEC under CIK 842023. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TECH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIO-TECHNE Corp directly from SEC EDGAR. BIO-TECHNE Corp's 13F Pro composite quality score has ranged between 53 and 74 since 2021, currently 58.9 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$321.2M
Net Income
Q2 2026
$54.6M
Free Cash Flow
Q2 2026
$86.9M
ROIC
Q2 2026
12.9%
D/E Ratio
Q2 2026
0.09
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-0.4% YoYNet Income
Operating Income
+146.3% YoYEPS (Diluted)
+152.2% YoYTotal Assets
+1.1% YoYTotal Debt
-42.2% YoYOp. Cash Flow
+1.6% YoYFree Cash Flow
+2.6% YoY| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $1.22B -0.4% | $1.22B +5.2% | $1.16B +2.0% | $1.14B +2.8% | $1.11B +18.7% | $931.0M |
| Net Income | — | $73.4M -56.3% | $168.1M -41.1% | $285.3M +4.9% | $272.1M +93.8% | $140.4M |
| Operating Income | $251.9M +146.3% | $102.3M -50.5% | $206.7M -30.9% | $298.9M +0.8% | $296.6M +25.0% | $237.3M |
| EPS (Diluted) | $1.16 +152.2% | $0.46 -56.2% | $1.05 -40.3% | $1.76 +324.1% | $0.41 +90.8% | $0.22 |
| Total Assets | $2.59B +1.1% | $2.56B -5.4% | $2.70B +2.5% | $2.64B +15.0% | $2.29B +1.4% | $2.26B |
| Total Debt | $200.0M -42.2% | $346.0M +8.5% | $319.0M -8.9% | $350.0M +36.8% | $255.9M -25.0% | $341.3M |
| Operating Cash Flow | $292.1M +1.6% | $287.6M -3.8% | $299.0M +17.5% | $254.4M -21.8% | $325.3M -7.6% | $352.2M |
| Free Cash Flow | $263.2M +2.6% | $256.6M +8.7% | $236.1M +9.2% | $216.1M -22.9% | $280.4M -8.9% | $307.9M |
Get alerted when TECH's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BIO-TECHNE Corp including:
Top Institutional Holders of TECH
BlackRock, Inc.
$990.9M14,025,816 shFMR LLC
$904.0M12,794,784 shVANGUARD CAPITAL MANAGEMENT LLC
$721.9M10,218,558 shGOLDMAN SACHS GROUP INC
$518.8M7,343,324 shHBK INVESTMENTS L P
$482.2M6,825,000 shVANGUARD PORTFOLIO MANAGEMENT LLC
$459.7M6,506,360 shMORGAN STANLEY
$450.4M6,374,717 shSTATE STREET CORP
$422.5M5,980,370 shGEODE CAPITAL MANAGEMENT, LLC
$377.5M5,351,464 shInvesco Ltd.
$352.3M4,986,424 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $990.9M | 14,025,816 |
| FMR LLC | $904.0M | 12,794,784 |
| VANGUARD CAPITAL MANAGEMENT LLC | $721.9M | 10,218,558 |
| GOLDMAN SACHS GROUP INC | $518.8M | 7,343,324 |
| HBK INVESTMENTS L P | $482.2M | 6,825,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $459.7M | 6,506,360 |
| MORGAN STANLEY | $450.4M | 6,374,717 |
| STATE STREET CORP | $422.5M | 5,980,370 |
| GEODE CAPITAL MANAGEMENT, LLC | $377.5M | 5,351,464 |
| Invesco Ltd. | $352.3M | 4,986,424 |
Companies Similar to TECH
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
REPLIGEN CORP
WEST PHARMACEUTICAL SERVICES INC
ALIGN TECHNOLOGY INC
Lantheus Holdings, Inc.
UNITED THERAPEUTICS Corp
DEXCOM INC
Penumbra Inc
MERIT MEDICAL SYSTEMS INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put TECH on your watchlist
Track score changes the day BIO-TECHNE Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TECH a good stock to buy?
13F Pro's AI-powered analysis of BIO-TECHNE Corp (TECH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TECH are available on the TECH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TECH is classified as a large company.
Which hedge funds own TECH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TECH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIO-TECHNE Corp's investment landscape.